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This United States community study evaluated the combination of daratu-
mumab, bortezomib, cyclophosphamide and dexamethasone (D-VCd) in
newly diagnosed multiple myeloma (NDMM) and relapsed multiple mye-
loma (RMM). Patients received 4–8 induction cycles of bortezomib
15 mg/m2, cyclophosphamide 300 mg/m2 and dexamethasone 40 mg
weekly. Intravenous daratumumab 16 mg/kg was administered as approved
except for a split-first dose in Cycle 1. Eligible patients underwent autolo-
gous stem cell transplantation. All patients received ≤12 daratumumab
maintenance doses monthly. Eighty-six NDMM and 14 RMM patients
received ≥1 treatment dose. In NDMM patients, very good partial response
or better (≥VGPR) and overall response rates after 4 induction cycles were
44% (primary endpoint) and 79%, respectively, and 56% and 81% at end
of induction. The 12-month progression-free survival (PFS) rate was 87%.
Efficacy was also observed in RMM patients. Fatigue (59%) and neutrope-
nia (13%) were the most frequent treatment-emergent adverse event
(TEAE) and grade 3/4 TEAE, respectively. Infusion reactions occurred in
54% of patients, primarily during the first dose, and were mild (2% grade
3). The first 2 daratumumab infusions were 45 and 38 h (median). Over-
all, D-VCd was well tolerated, split-first daratumumab dosing was feasible,
the ≥VGPR rate after 4 cycles was 44% and the 1-year PFS rate was 87%.
Keywords: daratumumab, multiple myeloma, cyclophosphamide, bortezomib,
LYRA.
Over the past decade, advances in treatment options have
improved clinical outcomes for patients with multiple mye-
loma (MM); however, despite these advances, patients even-
tually relapse and require subsequent therapy (Kumar et al,
2012a; Ocio et al, 2014). The duration and depth of response
is reduced with each relapse, resulting from lower sensitivity
of heavily treated patients to subsequent therapy (Borrello,
2012; Kurtin, 2013). Therefore, the treatment with the most
effective regimen in the frontline setting may provide the
best approach to achieve deep and durable clinical responses.
Proteasome inhibitors (PIs) and immunomodulatory
drugs (IMiDs) are commonly used to treat MM and have
demonstrated improved efficacy when administered in com-
bination with other agents (e.g., monoclonal antibodies, alky-
lating drugs, corticosteroids) versus monotherapy (Reeder
et al, 2014). Triplet combinations are commonly used as
induction therapy in MM (Moreau et al, 2017). Bortezomib,
cyclophosphamide and dexamethasone (VCd) is an IMiD-
sparing regimen that has demonstrated high response rates
and a tolerable safety profile in newly diagnosed MM
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(NDMM), leading to its widespread use as induction therapy
in transplant-eligible and ineligible patients (Reeder et al, 2009,
2010; Khan et al, 2012; Kumar et al, 2012b; Jimenez Zepeda
et al, 2014; Areethamsirikul et al, 2015). However, a standard
VCd dosing protocol has not been implemented across studies
or in clinical practice, contributing in part to different response
rates reported in clinical trials (Reeder et al, 2009, 2010; Khan
et al, 2012; Kumar et al, 2012b; Mai et al, 2015). In clinical
studies of VCd in NDMM patients, rates of very good partial
response (VGPR) or better ranged from 13% to 70% during
induction therapy (Reeder et al, 2009, 2010; Kumar et al,
2012b; Jimenez Zepeda et al, 2014; Mai et al, 2015).
Daratumumab, a human monoclonal antibody targeting
CD38, provides superior clinical benefit across lines of MM
therapy when combined with other regimens. In combination
with an IMiD [lenalidomide (R); plus dexamethasone (d)] or
with bortezomib [plus dexamethasone (Vd) or plus prednisone
and melphalan (VMP)], daratumumab-containing regimens
induce deep and durable responses, reduce the risk of disease
progression or death by ≥50%, and have tolerable safety profiles
(Dimopoulos et al, 2016; Palumbo et al, 2016; Mateos et al,
2018). These findings led to the approval of daratumumab-
based treatment for MM across multiple lines of therapy. Dara-
tumumab is approved in combination with Rd or Vd for
relapsed MM (RMM) patients who received ≥1 prior therapy,
and in combination with pomalidomide and dexamethasone for
RMM patients with ≥2 prior therapies, including lenalidomide
and a PI (http://www.janssenlabels.com/package-insert/produc
t-monograph/prescribing-information/DARZALEX-pi.pdf).
Most recently, daratumumab in combination with the PI/alkyla-
tor/steroid regimen VMP (D-VMP) reduced the risk of disease
progression or death by 50% compared with VMP alone in
NDMM patients ineligible for autologous stem cell transplanta-
tion (ASCT), leading to the first approval of daratumumab in
the frontline setting (http://www.janssenlabels.com/package-
insert/product-monograph/prescribing-information/DARZA
LEX-pi.pdf; Mateos et al, 2018). The VMP regimen is not com-
monly used in some countries, especially the United States
(US); thus, there is an unmet need to evaluate other daratu-
mumab-based combination regimens, especially in newly diag-
nosed patients. As VCd is commonly used in the treatment of
MM, we conducted a multicentre, single-arm, phase 2 study
(LYRA; MMY2012) to evaluate the efficacy and safety of daratu-
mumab in combination with VCd (D-VCd) in patients with
newly diagnosed and RMM. This US community practice–based
study also evaluated split-dosing of the first daratumumab infu-
sion over 2 days to determine if such a schedule is well tolerated
and reduces infusion time on the first day of treatment.
Methods
Eligibility criteria
Patients were ≥18 years of age, had documented MM defined
by International Myeloma Working Group (IMWG) criteria
(Kumar et al, 2016), measurable disease, previously untreated
myeloma or relapsed myeloma with 1 prior line of therapy
(including an induction regimen that may have been fol-
lowed by ASCT and single-agent maintenance therapy), and
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status of ≤2. RMM patients must have achieved a par-
tial response (PR) or better with initial therapy before
disease progression. For patients with previously untreated
MM, an emergency steroid course (≤40 mg dexamethasone,
or equivalent, per day for ≤4 days) was permitted. Radiation
therapy for lytic bone disease was permitted prior to study
entry, during screening, and during Cycles 1–2. Per IMWG
criteria (Kumar et al, 2016), patients with measurable disease
had a serum M-protein level ≥10 g/l (≥50 g/l in IgA, IgD,
IgE or IgM disease) or urine M-protein ≥200 mg/24 h. For
patients with light chain MM, serum immunoglobulin free
light chain (FLC) ≥01 g/l and an abnormal serum
immunoglobulin j:k FLC ratio was required. Eligible patients
had haemoglobin >75 g/l; absolute neutrophil count
>10 9 109/l; alanine aminotransferase and aspartate amino-
transferase <259 upper limit of normal; total bilirubin
<159 upper limit of normal; creatinine clearance >20 ml/
min/173 m2; corrected serum calcium ≤35 mmol/l or free
ionized calcium ≤1625 mmol/l; and a platelet count
≥75 9 109/l in patients in whom <50% of bone marrow
nucleated cells were plasma cells (>50 9 109/l, otherwise).
Patients were excluded if they were refractory to a PI or a
PI and IMiD combination, defined as failure to respond or
progression within 60 days of the end of PI therapy. Other
exclusion criteria included clinical signs or a history of
meningeal or central nervous system involvement by MM,
chronic obstructive pulmonary disease (forced expiratory vol-
ume in 1 s <50% of predicted normal), clinically significant
cardiac disease {including myocardial infarction within
6 months of Cycle 1 Day 1, New York Heart Association
Class III–IV congestive heart failure, uncontrolled cardiac
arrhythmia [National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE) Version 4.03,
https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-
14_QuickReference_5x7.pdf; grade ≥2]}, baseline QT inter-
val (QTc) >470 ms for 12-lead electrocardiogram (ECG) at
screening, moderate or severe persistent asthma within the
past 2 years, plasma cell leukaemia (>20 9 109/l circulating
plasma cells by standard differential), Waldenstr€om
macroglobulinaemia, POEMS syndrome (Polyneuropathy,
Organomegaly, Endocrinopathy, Monoclonal protein, Skin
changes), amyloid light chain amyloidosis, human immun-
odeficiency virus seropositivity, hepatitis B surface antigen
positivity, or a history of hepatitis C.
Study design
This was a multicentre, single-arm, open-label phase 2 study
of D-VCd in patients with NDMM, irrespective of eligibility
for high-dose chemotherapy and ASCT, or RMM following
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1 prior line of therapy (Fig 1). Planned enrolment was
100 patients with ≥40 previously untreated patients. Due to
slow recruitment of RMM patients, this cohort was subse-
quently closed to enrolment. Patients received 4–8 cycles of
induction therapy with bortezomib 15 mg/m2 (subcuta-
neous) on Days 1, 8 and 15; cyclophosphamide 300 mg/m2
(oral) on Days 1, 8, 15 and 22 of each 28-day cycle; and
weekly dexamethasone 40 mg [oral or intravenous (IV)]. In
Cycle 1 only, dexamethasone 20 mg was administered on
Days 1 and 2, resulting in a total weekly dose of 40 mg.
Patients received daratumumab 8 mg/kg IV on Days 1 and 2
of Cycle 1. Daratumumab 16 mg/kg was administered weekly
from Cycle 1 Day 8 to the end of Cycle 2, every 2 weeks in
Cycles 3–6, and every 4 weeks thereafter. The allowable range
of 4–8 induction cycles was permitted due to differences in
local standard of care across US community settings and due
to the enrolment of both transplant eligible and ineligible
patients. After induction therapy, eligible patients could
receive a transplant conditioning regimen and ASCT at the
discretion of the investigator. Following induction and/or
conditioning/ASCT, patients received ≤12 cycles of daratu-
mumab 16 mg/kg maintenance therapy every 4 weeks. Dara-
tumumab maintenance therapy commenced approximately
90 days after ASCT when appropriate. Follow-up will con-
tinue through 36 months from the start of induction.
All patients received pre-infusion medication on daratu-
mumab dosing days (≤3 h before dosing) comprising oral
dexamethasone 40 mg (20 mg IV on Days 1, 2, 8, 15 and 22
of Cycle 1; 12 mg during maintenance cycles), acetamino-
phen 650–1000 mg IV or oral, diphenhydramine 25–50 mg
IV or oral (or equivalent), and an optional leukotriene inhi-
bitor (montelukast 10 mg oral or equivalent). Post-infusion
medication included oral dexamethasone 4 mg on Cycle 1
Day 3 and 20 mg on Cycle 1 Day 9, 16 and 23. Additional
medications, including an antihistamine, leukotriene
inhibitor, short-acting b2 adrenergic receptor agonist, or
control medications for lung disease, were administered for
patients with a higher risk of respiratory complications.
Study endpoints and analyses
The primary endpoint was the rate of complete
response + very good partial response (CR + VGPR) follow-
ing 4 cycles of induction therapy with D-VCd in patients with
newly diagnosed or RMM. The primary endpoint was mea-
sured after all enrolled patients had completed 4 cycles of
induction therapy or had discontinued by the time of analysis.
The primary hypothesis was that >60% of patients with
NDMM and >30% of patients with RMM would achieve either
CR or VGPR following 4 cycles of induction therapy. Disease
response and progression were evaluated according to IMWG
criteria (Kumar et al, 2016). Efficacy assessments included
serum and urine M-protein measurements, serum and urine
immunofixation electrophoresis, serum FLC, serum calcium
corrected for albumin, serum immunoglobulins, and examina-
tion of bone marrow aspirate or biopsy. Extramedullary plas-
macytomas present at screening or as clinically indicated were
assessed by clinical examination or radiological imaging.
Major secondary efficacy endpoints included overall
response rate (ORR), time to VGPR or better, time to PR or
better, duration of response, progression-free survival (PFS)
and overall survival (OS). ORR was measured following
4 cycles of induction therapy, at the end of 4–8 cycles of
induction therapy and after all 12 cycles of maintenance
therapy. The rate of CR + VGPR at the end of induction,
following 4–8 cycles of therapy, was also assessed. Time to
response was measured from the start of induction therapy
to the date of initial response documentation, confirmed by
a repeated measurement. Duration of response was defined
as the time from the initial documentation of a response (PR
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Fig 1. LYRA study design. aRange of 4–8 induction cycles due to differences in local standard of care across study sites and enrolment of both
transplant eligible, transplant ineligible and relapsed patients. bIn Cycle 1, 20 mg dexamethasone was given on Days 1 and 2 and weekly there-
after. cIn patients who underwent ASCT, maintenance therapy was to begin approximately 90 days after ASCT. ASCT, autologous stem cell trans-
plantation; HDT, high-dose therapy; IV, intravenously; PO, orally; SC, subcutaneously; VCd, bortezomib, cyclophosphamide and dexamethasone.
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or better) to the first documented evidence of progressive
disease.
Patients with a response of VGPR who had negative M-
protein by serum M-protein quantitation by electrophoresis
(SPEP) received a reflex serum immunofixation (IFE) test to
confirm the presence of daratumumab on IFE. Patients with
positive serum IFE and confirmed daratumumab IFE inter-
ference who met all other clinical criteria for CR or stringent
CR (sCR) were considered to have responses of CR/sCR.
Safety and tolerability were assessed by laboratory test
abnormalities and the incidence of adverse events (AEs),
including infusion reactions (IRs). Safety evaluations
included AE monitoring, clinical laboratory parameters
(haematology and serum chemistry), ECG monitoring (at
screening only), vital sign measurements, physical examina-
tions and ECOG performance status. AEs were reported for
the duration of the study. Vital signs were monitored regu-
larly during the split-dose infusion and other doses of dara-
tumumab. Toxicities were graded using the NCI-CTCAE
Version 4.03 (https://www.eortc.be/services/doc/ctc/CTCAE_
4.03_2010-06-14_QuickReference_5x7.pdf). An Internal Data
Review Committee evaluated 3 prespecified interim safety
analyses after ≥20 patients received ≥1 induction cycle, after
≥50 patients completed Cycle 1 (with a focus on IRs during
Cycle 1), and after ≥50 patients received ≥4 induction cycles.
Exploratory endpoints included efficacy in high-risk molecu-
lar subgroups, including del(17p), t(4;14) and t(14;16).
Stem cell collection
Eligible patients could undergo stem cell collection, high-dose
therapy and ASCT following 4–8 cycles of induction. Criteria,
testing and treatment for patients undergoing ASCT followed
the standard operating procedures of the transplant centre.
Study oversight
The study was sponsored by Janssen Scientific Affairs, LLC
and registered at ClinicalTrials.gov (identification number:
NCT02951819). The research was approved by the clinical
study sites’ institutional review boards or ethics committees,
and all patients gave written informed consent. Janssen Sci-
entific Affairs, LLC funded writing assistance.
Statistical analyses
Responses to treatment and disease progression were evalu-
ated by a validated computer algorithm to calculate IMWG
response. For each response category, a 2-sided 95% confi-
dence interval (CI) was calculated. In a study of VCd, a
VGPR or better rate of 61% was reported (Reeder et al,
2009). This response rate was the basis for the assumption
used for the present study. With a planned enrolment of
100 patients (minimum of 40 NDMM patients), ≥80% power
was needed to detect an absolute 20% increase in the
untreated cohort at the 5% 1-sided significance level. Time-
to-event efficacy evaluations, including duration of response
(PR or better), time to progression, PFS and OS, were sum-
marized with descriptive statistics using the Kaplan–Meier
method. Due to slow recruitment of patients with RMM, the
protocol was amended to close this cohort. Therefore, no
inferential statistics were performed on the relapsed cohort.
Treatment-emergent adverse events (TEAEs) and clinical lab-
oratory test results were summarized.
Data sharing statement
The data sharing policy of Janssen Pharmaceutical Compa-
nies of Johnson & Johnson is available at https://www.jansse
n.com/clinical-trials/transparency. As noted on this site,
requests for access to the study data can be submitted




A total of 101 patients were enrolled, including 87 patients
with NDMM and 14 patients with RMM. Patient demograph-
ics and baseline disease characteristics in all treated patients
are presented in Table I. The median (range) age in the com-
bined study population was 64 (41–82) years with 14 (140%)
patients aged ≥75 years; 810% were white. Ninety-four per-
cent of patients had a baseline ECOG performance status of 0
or 1. Among patients evaluated for biomarkers (n = 96),
34 (354%) had high-risk cytogenetic abnormalities, including
30 (366%) with NDMM and 4 (286%) with RMM. Median
(range) time from diagnosis was 008 (00–31) years among
patients with NDMM and 222 (00–58) years for those with
RMM. Median follow-up time for patients with newly diag-
nosed or RMM was 79 and 88 months, respectively.
Disposition and drug exposure
At the clinical cut-off date of 10 January 2018, 14 patients
had discontinued treatment resulting from progressive dis-
ease (n = 5), other reasons (n = 4), AEs (n = 2), patient
withdrawal (n = 1), refusal of further treatment (n = 1) and
death (n = 1; Table II). One hundred patients received
≥1 dose of D-VCd and were included in the safety analysis
set, including 86 patients with NDMM and all 14 patients
with RMM. At the time of the analysis, the median (range)
duration of study treatment was 225 (50–441) days, includ-
ing a median of 225 (50–441) days for NDMM patients and
a median of 2355 (71–394) days in patients with RMM.
The total treated population received a median (range) of
8 (2–15) treatment cycles, with 95 (950%) patients having
completed ≥4 cycles. Patients with NDMM received a med-
ian (range) of 8 (2–15) treatment cycles versus 9 (3–15)
LYRA: Daratumumab Plus VCd in Multiple Myeloma
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cycles in patients with RMM. Patients with NDMM received
a median (range) of 60 (2–8) treatment cycles during induc-
tion versus a median (range) of 75 (3–8) induction cycles
for patients with RMM. The median cumulative dose of
daratumumab and bortezomib received during induction
Cycles 1–4 was 1920 mg/kg (1920 mg/kg expected per pro-
tocol) and 180 mg/m2 (180 mg/m2 expected per protocol),
respectively, and was similar in the newly diagnosed and
RMM cohorts. For cyclophosphamide exposure, 6 (60%)
patients had a reduced dose of the drug during Cycles 1–4.
Among all treated patients, the median (range) infusion time
for daratumumab was 45 (1–25) h on Cycle 1 Day 1 and
38 (3–5) h on Cycle 1 Day 2. Median (range) infusion dura-
tions were similar (35 [0–6] h) for subsequent infusions.
Efficacy
Analyses of primary and secondary efficacy variables were
based on the response-evaluable population, which included
patients with measurable disease at baseline or screening who
received ≥1 dose of study treatment and had ≥1 post-baseline
disease assessment. In the 86 response-evaluable patients with
NDMM, the rate of CR + VGPR (primary endpoint) after
4 cycles of induction therapy was 442% (95% CI, 335–
553%), including 4 [47% (95% CI, 13–115%)] patients
who achieved CR. The ORR after 4 cycles of induction ther-
apy was 791% (95% CI, 690–871%; Fig 2A). At the end
of induction, the ORR was 814% (95% CI, 716–890%),
with 48 [558% (95% CI, 447–665%)] patients achieving
Table I. Demographics and baseline disease characteristics of treated patients.*
NDMM (n = 86) RMM (n = 14) Total (n = 100)
Age, median (range), years 63 (41–82) 68 (48–78) 64 (41–82)
<65 years, n (%) 45 (523) 6 (429) 51 (510)
65 to <75 years, n (%) 31 (360) 4 (286) 35 (350)
≥75 years, n (%) 10 (116) 4 (286) 14 (140)
Sex, n (%)
Male 54 (628) 10 (714) 64 (640)
Female 32 (372) 4 (286) 36 (360)
Race, n (%)
White 67 (779) 14 (1000) 81 (810)
Black or African American 11 (128) 0 (0) 11 (110)
Unknown 6 (70) 0 (0) 6 (60)
Asian 2 (23) 0 (0) 2 (20)
ECOG performance status, n (%)
0 40 (465) 6 (429) 46 (460)
1 41 (477) 7 (500) 48 (480)
2 5 (58) 1 (71) 6 (60)
Type of myeloma, n (%)
IgG 52 (605) 5 (357) 57 (570)
IgA 15 (174) 2 (143) 17 (170)
IgM 1 (12) 0 (0) 1 (10)
IgD 2 (23) 0 (0) 2 (20)
Light chain 13 (151) 6 (429) 19 (190)
ISS staging, n (%)†
I 29 (337) 2 (143) 31 (310)
II 31 (360) 3 (214) 34 (340)
III 26 (302) 9 (643) 35 (350)
Time since initial diagnosis, median (range), years 008 (00–31) 222 (04–58) 009 (00–58)
Cytogenetic abnormality, n (%) (n = 82) (n = 14) (n = 96)
Standard risk 52 (634) 10 (714) 62 (646)
High risk‡ 30 (366) 4 (286) 34 (354)
del17p§ 6 (73) 0 (0) 6 (63)
t(4;14) 19 (232) 3 (214) 22 (229)
t(14;16) 26 (317) 3 (214) 29 (302)
ECOG, Eastern Cooperative Oncology Group; FISH, fluorescence in situ hybridisation; Ig, immunoglobulin; ISS, International Staging System;
NDMM, newly diagnosed multiple myeloma; RMM, relapsed multiple myeloma.
*Percentages may not add up to 100% due to rounding.
†ISS staging was captured in the case report form.
‡Any of del(17p), t(4:14) or t(14:16).
§del(17p) was detected by a TP53 FISH probe.
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VGPR + CR and 8 [93% (95% CI, 41–175%)] patients
achieving CR. Responses continued to deepen in patients
who had entered the maintenance phase (data not shown).
In patients with NDMM, median time to PR or better was
10 (95% CI, 10–10) month and median time to VGPR or
better was 46 (95% CI, 28–64) months. Median duration
of response was not reached. Among enrolled patients with
NDMM (n = 87), median PFS was not reached [95% CI, not
evaluable (NE)-NE], and the 12-month PFS rate was 870%
(95% CI, 571–966%; Fig 2B). At the time of clinical cut-
off, the 12-month OS rate was 988% (95% CI, 920–998%)
for patients with NDMM.
Among patients in the small cohort with RMM (n = 14),
the rate of CR + VGPR (primary endpoint) after 4 cycles of
induction therapy was 571% (95% CI, 289–823%). The
ORR after 4 induction cycles was 714% (95% CI, 419–
916%), including 2 [143% (95% CI, 18–428%)] patients
with CR. At the end of induction, the ORR was 714% (95%
CI, 419–916%), with 9 [643% (95% CI, 351–872%)]
patients achieving VGPR + CR and 3 [214% (95% CI, 47–
508%)] patients achieving CR. Median time to PR or better
was 10 (95% CI, 09–NE) month, median time to VGPR or
better was 18 (95% CI, 10–NE) months, and median dura-
tion of response was 124 (95% CI, 37–124) months. Med-
ian PFS was 133 (95% CI, 68–133) months and the
12-month PFS rate was 662% (95% CI, 324–860%). At the
time of clinical cut-off, the 12-month OS rate was 545%
(95% CI, 86–861%).
Safety
Among patients with NDMM, the most frequent any-grade
TEAE was fatigue (616%), and the most frequent grade 3/4
TEAE was neutropenia (116%; Table III). Serious TEAEs
occurred in 19 (221%) patients with NDMM, and the most
frequent (≥2 patients) included atrial fibrillation (35%),
Table II. Patient disposition.
NDMM (n = 87) RMM (n = 14) Total (N = 101)
Treatment discontinuation, n (%) 10 (115) 4 (286) 14 (139)
Other 4 (46)* 0 (0) 4 (40)*
Adverse event 2 (23) 0 (0) 2 (20)
Progressive disease 2 (23) 3 (214) 5 (50)
Patient refused further study treatment 1 (11) 0 (0) 1 (10)
Withdrawal by patient 1 (11) 0 (0) 1 (10)
Death 0 (0) 1 (71)† 1 (10)
In the NDMM cohort, 1 patient discontinued prior to receiving study treatment.
AE, adverse event; NDMM, newly diagnosed multiple myeloma; PR, partial response; RMM, relapsed multiple myeloma.
*“Other” included lack of response to study regimen (n = 1), PR not achieved after 6 cycles (n = 1), investigator decision (patient did not
respond to study treatment; n = 1), and patient not treated (n = 1).






























































Fig 2. ORR in Cycles 1–4 and end of induction (A) and progression-free survival (B) in newly diagnosed multiple myeloma patients treated with
daratumumab plus VCd. Responses may not add up to the total response rates due to rounding. CR, complete response; ORR, overall response
rate; PR, partial response; VCd, bortezomib, cyclophosphamide and dexamethasone; VGPR, very good partial response.
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pulmonary embolism (23%), bacteraemia (23%) and men-
tal status changes (23%). Three patients experienced a seri-
ous TEAE related to daratumumab, including bacteraemia,
viral upper respiratory tract infection and vomiting (1 each).
Among patients with RMM, the most frequent TEAEs
included fatigue, diarrhoea and upper respiratory tract infec-
tion (429% each), whereas the most frequent grade 3/4
TEAE was neutropenia (214%). Serious TEAEs occurred in
2 patients with RMM, which were not considered to be dara-
tumumab-related.
A total of 540% of patients experienced IRs (Table IV).
In the combined study population, IRs occurred in
49 (490%) patients on Cycle 1 Day 1 and in 4 (40%)
patients on Cycle 1 Day 2. The most frequent IRs (>5%)
were chills (130%), cough (90%), dyspnoea (80%), pruri-
tus (70%) and nausea (70%). Less frequent events, includ-
ing hypertension, hypersensitivity, chest discomfort, fatigue,
nasal congestion, rash and decreased oxygen saturation, were
each reported in 3 (30%) patients. IRs were generally mild;
in all patients only 2 (20%), both with NDMM, developed
grade 3 IRs (hypertension and anaphylactic reaction). No
grade 4 or 5 IRs were reported, and no patients discontinued
daratumumab treatment due to an IR.
A total of 3 (30%) patients experienced TEAEs that led to
permanent discontinuation of all study treatment. Among
the 3 patients who permanently discontinued treatment,
2 patients died due to AEs unrelated to study treatment
(nephrotic syndrome and sudden death) and 1 patient expe-
rienced worsening of atrial fibrillation. Two additional
patients, both with RMM, died due to progressive disease.
Stem cell transplant
At the time of clinical cut-off, 28 (326%) patients with
NDMM had undergone ASCT. In the 26 patients for whom
data were available, 25 received a transplant conditioning
Table III. Most frequent any grade (>25%) and grade 3/4 (≥10%) TEAEs.
Event, n (%)
NDMM (n = 86) RMM (n = 14) Total (N = 100)
Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4
Total TEAEs 86 (1000) 48 (558) 14 (1000) 8 (571) 100 (1000) 56 (560)
Fatigue 53 (616) 6 (70) 6 (429) 0 (0) 59 (590) 6 (60)
Nausea 38 (442) 1 (12) 3 (214) 0 (0) 41 (410) 1 (10)
Diarrhoea 31 (360) 3 (35) 6 (429) 1 (71) 37 (370) 4 (40)
Insomnia 26 (302) 0 (0) 2 (143) 0 (0) 28 (280) 0 (0)
Cough 25 (291) 0 (0) 5 (357) 0 (0) 30 (300) 0 (0)
Constipation 24 (279) 0 (0) 0 (0) 0 (0) 24 (240) 0 (0)
Vomiting 22 (256) 2 (23) 5 (357) 0 (0) 27 (270) 2 (20)
Upper respiratory tract infection 18 (209) 0 (0) 6 (429) 0 (0) 24 (240) 0 (0)
Back pain 16 (186) 0 (0) 4 (286) 1 (71) 20 (200) 1 (10)
Neutropenia 11 (128) 10 (116) 3 (214) 3 (214) 14 (140) 13 (130)
Myalgia 9 (105) 0 (0) 5 (357) 0 (0) 14 (140) 0 (0)
Viral upper respiratory tract infection 7 (81) 1 (12) 5 (357) 0 (0) 12 (120) 1 (10)
NDMM, newly diagnosed multiple myeloma; RMM, relapsed multiple myeloma; TEAE, treatment-emergent adverse event.
Event, n (%)
NDMM (n = 86) RMM (n = 14) Total (N = 100)
Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4
Total IRs 46 (535) 2 (23) 8 (571) 0 (0) 54 (540) 2 (20)
Chills 12 (140) 0 (0) 1 (71) 0 (0) 13 (130) 0 (0)
Cough 6 (70) 0 (0) 3 (214) 0 (0) 9 (90) 0 (0)
Dyspnoea 7 (81) 0 (0) 1 (71) 0 (0) 8 (80) 0 (0)
Pruritus 7 (81) 0 (0) 0 (0) 0 (0) 7 (70) 0 (0)
Nausea 7 (81) 0 (0) 0 (0) 0 (0) 7 (70) 0 (0)
Flushing 5 (58) 0 (0) 0 (0) 0 (0) 5 (50) 0 (0)
Vomiting 4 (47) 0 (0) 0 (0) 0 (0) 4 (40) 0 (0)
Pyrexia 4 (47) 0 (0) 0 (0) 0 (0) 4 (40) 0 (0)
Hyperhidrosis 3 (35) 0 (0) 1 (71) 0 (0) 4 (40) 0 (0)
IR, infusion reaction; NDMM, newly diagnosed multiple myeloma; RMM, relapsed multiple
myeloma.
Table IV. Most frequent (>3 patients) IRs.
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regimen of full dose melphalan 200 mg/m2, and 1 received a
reduced dose of melphalan 140 mg/m2. The median number
of CD34+ cells collected from eligible patients in whom stem
cell data were available was 50 (range: 2–13) 9 106 cells/kg.
Discussion
These results demonstrate that D-VCd can be safely adminis-
tered and induces VGPR or better in the community setting,
providing an IMiD-sparing regimen for patients with
NDMM. Additionally, this study indicates that dividing the
first daratumumab dose over 2 days is feasible, results in a
reduced duration of the first infusion without an increase in
IRs, and facilitates administration of the first weekly daratu-
mumab dose in the community setting.
After 4 cycles of induction therapy, CR + VGPR was
achieved in 442% (47% CR) of patients with NDMM,
which increased to 558% (93% CR) at the end of induc-
tion, demonstrating that longer treatment with daratumumab
provides additional benefit by increasing the depth of
response. This finding is consistent with other clinical studies
of daratumumab (Dimopoulos et al, 2016, 2017; Palumbo
et al, 2016; Chari et al, 2017a,b; Facon et al, 2017; Spencer
et al, 2017), in which responses deepened with longer treat-
ment duration. Similar response rates were observed in the
small number of patients with RMM enrolled in LYRA, but
additional patients are needed to evaluate the efficacy and
safety of D-VCd in this population.
The rate of CR + VGPR was less than the hypothesized
rate of 60% for patients with NDMM. The estimated 60%
rate was based on a small study conducted in 33 transplant-
eligible patients at 2 academic centres (Reeder et al, 2009),
while our study enrolled patients with transplant-eligible and
ineligible MM, mostly at community-based sites. Indeed, the
LYRA clinical trial is the second largest study of VCd, and
the only larger study reported a 37% rate of VGPR or better
(Mai et al, 2015). Furthermore, the lack of a consensus VCd
regimen makes cross-study comparisons challenging. We uti-
lized the regimen of Jimenez-Zepeda et al (2015) because this
regimen administered weekly bortezomib using a schedule
(Days 1, 8 and 15 every 28 days) utilized in routine clinical
practice by most of the centres participating in this study.
The weekly scheduling was also more convenient and less
burdensome for the community-based patients. However,
this regimen uses a lower dose intensity of bortezomib and
dexamethasone than older VCd regimens, and it is unknown
whether the relatively low bortezomib and dexamethasone
dose intensities negatively impacted the rate of VGPR or bet-
ter, especially after only 4 treatment cycles.
The importance of chemotherapy dose intensity in treat-
ment with VCd was suggested by the phase 2 EVOLUTION
study. The rate of VGPR or better was 13% after 4 cycles of
induction therapy for patients who received cyclophos-
phamide 500 mg/m2 on Days 1 and 8 of each 21-day cycle
(Kumar et al, 2012b). An amendment that added a Day 15
dose of cyclophosphamide resulted in a 41% rate of VGPR
or better, suggesting that modifying the VCd regimen to
increase chemotherapy dose intensity may improve efficacy
(Kumar et al, 2012b). In line with these findings, an Inter-
groupe Francophone du Myelome study administered borte-
zomib 13 mg/m2 on Days 1, 4, 8 and 11; cyclophosphamide
500 mg/m2 on Days 1, 8 and 15; and dexamethasone 40 mg
on Days 1–4 and 9–12 of each 21-day cycle to 169 patients
with NDMM. The ORR was 834%, including a 562% rate
of VGPR or better, after 4 induction cycles (Moreau et al,
2016). These findings indicate that the lower cyclophos-
phamide, bortezomib and dexamethasone doses administered
in the LYRA study may have adversely impacted the response
rates.
Differences in disease characteristics in this study, versus
other VCd studies and the phase 3 ALCYONE study of D-
VMP in NDMM, may have also affected response rates. For
example, we enrolled many more newly diagnosed patients
with high cytogenetic risk (366%) versus only 169% of
patients in ALCYONE (Mateos et al, 2018). Conversely,
ECOG performance status scores were better than for
patients in ALCYONE. Despite the observed differences in
response rates, the 12-month PFS rates in the LYRA and
ALCYONE studies were comparable (870% vs. 867%,
respectively). This finding indicates that early response may
not directly correlate with PFS. As the depth of response
with daratumumab improved over time, early response to
treatment may not be as important as best response after
completion of induction or maintenance therapy. Follow-up
for efficacy is ongoing.
The patient demographics and disease characteristics were
consistent with those observed in NDMM patients in a com-
munity setting (Jagannath et al, 2018). However, the conduct
of this study in a community setting may have impacted the
observed response rates. For example, in a study conducted
at a single academic centre evaluating 224 patients with pre-
viously untreated chronic lymphocytic leukaemia (CLL), a
fludarabine, cyclophosphamide and rituximab (FCR) regimen
demonstrated CR and ORR rates of 70% and 95%, respec-
tively (Keating et al, 2005). However, a study of FCR in
86 evaluable, previously untreated or minimally treated CLL
patients in a community setting reported CR and ORR rates
of 14% and 59%, respectively (Reynolds et al, 2012). The
authors concluded that the use of an alternative FCR regi-
men, differences in patient characteristics compared with
academic studies, and challenges related to obtaining all
assessments needed for full evaluations contributed to the
lower than expected response rates (Reynolds et al, 2012).
Our study highlights the need to evaluate treatment regimens
in community patients to better understand the true efficacy
and safety in a real-world setting.
This study demonstrates that daratumumab can be safely
combined with VCd in the community setting. Early findings
from prespecified interim safety analyses of this study war-
ranted its continuation as planned, and the tolerability
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profile was consistent with previous reports of VCd and
daratumumab. TEAEs were largely manageable, with only
3 patients experiencing a TEAE resulting in permanent dis-
continuation of all study treatment. While the incidence of
TEAEs was largely similar between patient groups, those with
RMM had a numerically higher rate of infections and neu-
tropenia versus patients with NDMM.
In clinical trials of daratumumab (1166 patients) the inci-
dence of IRs was 40%, 2% and 4% with the first, second and
subsequent infusions, respectively (http://www.janssenlabels.c
om/package-insert/product-monograph/prescribing-informa
tion/DARZALEX-pi.pdf). Consistent with these findings, the
overall IR rate in the present study was 540%, and events were
predominantly mild (no grade ≥4 IRs) and occurred largely
during the first infusion (490%). While the IR rates with the
first split-dose infusion of daratumumab were numerically
higher (490%) in this study compared to the rates observed in
a phase 1 study of daratumumab-containing regimens
[MMY1001; daratumumab plus carfilzomib, lenalidomide and
dexamethasone (23%) or daratumumab plus carfilzomib and
dexamethasone (36%)], further investigation is warranted to
determine if differences in sample size or patient characteristics
impacted the rate of IRs (Chari et al, 2017b, 2018). Early evi-
dence in clinical trials suggests that splitting the first dose of
daratumumab over 2 days may improve convenience for
patients and health care providers by reducing infusion dura-
tion without affecting the pharmacokinetic profile of daratu-
mumab (Chari et al, 2017b, 2018; Lonial et al, 2017). Here,
splitting the first dose of daratumumab reduced the infusion
time on Cycle 1 Day 1 to 45 h compared with 70 h for a full
dose (http://www.janssenlabels.com/package-insert/product-
monograph/prescribing-information/DARZALEX-pi.pdf), sup-
porting the feasibility of split-first dosing of daratumumab in
patients with MM. As the duration of the daratumumab first
full infusion may be prolonged by the addition of pre- and
post-infusion medications, patient monitoring and mitigation
of IRs as needed, the ability to split the first dose of daratu-
mumab over 2 days provides patients and health care providers
with a safe and feasible option to reduce the duration of the
first daratumumab infusion.
Adding daratumumab to VCd resulted in no adverse
impact on stem cell collection or engraftment, confirming
that daratumumab combination therapy is feasible as part of
induction therapy for transplant-eligible NDMM patients.
These findings were consistent with those observed with
daratumumab in combination with carfilzomib, lenalidomide
and dexamethasone (EQUULEUS study) in NDMM (Chari
et al, 2017b), further supporting the use of daratumumab in
induction regimens. In the phase 3 CASSIOPEIA study
(NCT02541383), daratumumab in combination with borte-
zomib, thalidomide and dexamethasone is under investiga-
tion as induction and consolidation therapy in patients with
transplant-eligible NDMM.
In summary, D-VCd induces very good partial responses
in many patients and is a tolerable frontline regimen in
NDMM patients, regardless of transplant eligibility. The regi-
men provides an alternative to using IMiD-based treatments
as initial interventions when patient compliance with daily
oral therapy may be a factor. Depth of response improved
with additional cycles of therapy, indicating that longer treat-
ment with daratumumab provides additional clinical benefit.
Splitting the first daratumumab dose over 2 days was feasi-
ble, did not increase IRs, and reduced the time of the first
daratumumab infusion. While the LYRA study is limited by
the relatively small sample size, the lack of a control or
active-comparator arm, and a primary endpoint that, in ret-
rospect, may not have allowed time for deeper responses to
develop, these results demonstrate the feasibility of adding
daratumumab to VCd. These data also warrant investigation
of alternative VCd dosing regimens that may improve the
depth of response in patients with MM.
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